Return-Path: <bounce-mc.us2_5169274.1460755-3507c8b6d9@mail62.suw231.rsgsv.net>
Received: from gator4148.hostgator.com
	by gator4148.hostgator.com with LMTP
	id wBjHAP/skGOE1wgA7/vpDg
	(envelope-from <bounce-mc.us2_5169274.1460755-3507c8b6d9@mail62.suw231.rsgsv.net>); Wed, 07 Dec 2022 13:43:59 -0600
Return-path: <bounce-mc.us2_5169274.1460755-3507c8b6d9@mail62.suw231.rsgsv.net>
Envelope-to: gloria@caldonbiotech.com
Delivery-date: Wed, 07 Dec 2022 13:43:59 -0600
Received: from mail62.suw231.rsgsv.net ([198.2.174.62]:13819)
	by gator4148.hostgator.com with esmtps  (TLS1.2) tls TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384
	(Exim 4.95)
	(envelope-from <bounce-mc.us2_5169274.1460755-3507c8b6d9@mail62.suw231.rsgsv.net>)
	id 1p30Kk-002lm0-JI
	for gloria@caldonbiotech.com;
	Wed, 07 Dec 2022 13:43:58 -0600
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=captodayonline.com;
	s=k1; t=1670442228; x=1670744628; i=noreply@captodayonline.com;
	bh=qu6+MOJ3/RLRbwdZj25FcVkyX21nRoYMa6fLEyN35n0=;
	h=Subject:From:Reply-To:To:Date:Message-ID:X-MC-User:Feedback-ID:
	 List-ID:List-Unsubscribe:List-Unsubscribe-Post:Content-Type:
	 MIME-Version:CC:Date:Subject:From;
	b=DX2uzkUELQDbqF0voW45/guQgpxGlJ2nrtdDaw+NAxK9GVHXUfU7qV27EHrlDX3ew
	 Hj2CAgwaFyWeWy2KPEsVVh1TxvoLMHYRsDMuVMCOqEa7MSRUKOn9PChtcs5CvSIwom
	 VgNtwZayUVbK9TczBvwYcGlEPe/Vn7Jc2x+pLrMw=
Received: from localhost (localhost [127.0.0.1])
	by mail62.suw231.rsgsv.net (Mailchimp) with ESMTP id 4NS7500fk1zd95X
	for <gloria@caldonbiotech.com>; Wed,  7 Dec 2022 19:43:48 +0000 (GMT)
Subject: =?utf-8?Q?In=20toxicology=2C=20puzzling=20out=20the=20unexpected=20negative?=
From: =?utf-8?Q?CAP=20TODAY?= <noreply@captodayonline.com>
Reply-To: =?utf-8?Q?CAP=20TODAY?= <noreply@captodayonline.com>
To: =?utf-8?Q?Gloria=20Milich?= <gloria@caldonbiotech.com>
Date: Wed,  7 Dec 2022 19:43:40 +0000
Message-ID: <93f21bea2e282733bd0cd8d59.3507c8b6d9.20221207194327.993ff64907.3d6fa52a@mail62.suw231.rsgsv.net>
X-Mailer: Mailchimp Mailer - **CID993ff649073507c8b6d9**
X-Campaign: mailchimp93f21bea2e282733bd0cd8d59.993ff64907
X-campaignid: mailchimp93f21bea2e282733bd0cd8d59.993ff64907
X-Report-Abuse: Please report abuse for this campaign here: https://mailchimp.com/contact/abuse/?u=93f21bea2e282733bd0cd8d59&id=993ff64907&e=3507c8b6d9
X-MC-User: 93f21bea2e282733bd0cd8d59
Feedback-ID: 5169274:5169274.1460755:us2:mc
List-ID: 93f21bea2e282733bd0cd8d59mc list <93f21bea2e282733bd0cd8d59.778753.list-id.mcsv.net>
X-Accounttype: pr
List-Unsubscribe: <https://captodayonline.us2.list-manage.com/unsubscribe?u=93f21bea2e282733bd0cd8d59&id=1abd017e9e&e=3507c8b6d9&c=993ff64907>, <mailto:unsubscribe-mc.us2_93f21bea2e282733bd0cd8d59.993ff64907-3507c8b6d9@unsubscribe.mailchimpapp.net?subject=unsubscribe>
List-Unsubscribe-Post: List-Unsubscribe=One-Click
Content-Type: multipart/alternative; boundary="_----------=_MCPart_2031158919"
MIME-Version: 1.0
X-Spam-Status: No, score=2.5
X-Spam-Score: 25
X-Spam-Bar: ++
X-Spam-Flag: NO

This is a multi-part message in MIME format

--_----------=_MCPart_2031158919
Content-Type: text/plain; charset="utf-8"; format="fixed"
Content-Transfer-Encoding: quoted-printable

In cases of unexpected negative results in toxicology testing=2C avoid ove=
rinterpretation=2C know your assays and providers=2C and don=E2=80=99t put=
 off definitive testing when it=E2=80=99s needed=2C

https://www.captodayonline.com

In toxicology=2C puzzling out the unexpected negative (https://www.captoda=
yonline.com/in-toxicology-puzzling-out-the-unexpected-negative/) In cases=
 of unexpected negative results in toxicology testing=2C avoid overinterpr=
etation=2C know your assays and providers=2C and don=E2=80=99t put off def=
initive testing when it=E2=80=99s needed=2C though it=E2=80=99s not a pana=
cea. That=E2=80=99s some of the advice Nicholas Heger=2C PhD=2C NRCC=2C me=
dical director of clinical operations and lab support and co-director of c=
linical chemistry at Tufts Medical Center=2C shared in an AACC session in=
 July on toxicology investigations=2C focused on urine drug screening for=
 compliance and pain management and using his lab=E2=80=99s patient cases.
------------------------------------------------------------
https://diagnostics.roche.com/us/en/products/params/cobas-hbv-test.html?ut=
m_source=3DCAPTODAY&utm_medium=3DENEWSCOMBO&utm_id=3D2022&utm_term=3D1207&=
utm_content=3DVIROLOGY
FDA approves CDx for HER2-low metastatic breast cancer (https://www.captod=
ayonline.com/put-it-on-the-board-1122/) The Food and Drug Administration a=
pproved Roche=E2=80=99s Pathway anti-HER2/neu (4B5) rabbit monoclonal prim=
ary antibody to identify metastatic breast cancer patients with low HER2 e=
xpression for whom Enhertu may be considered a targeted treatment. Enhertu=
 is a specifically engineered HER2-directed antibody drug conjugate jointl=
y developed and commercialized by AstraZeneca and Daiichi Sankyo.
------------------------------------------------------------
https://diagnostics.roche.com/us/en/products/params/cobas-hbv-test.html?ut=
m_source=3DCAPTODAY&utm_medium=3DENEWSCOMBO&utm_id=3D2022&utm_term=3D1207&=
utm_content=3DVIROLOGY


** Q&A column (https://www.captodayonline.com/qa-column-1122/)
------------------------------------------------------------
Q. I want to inquire about verification of target mean/ranges for hematolo=
gy analytes. We run a control material 20 times and calculate statistics s=
uch as mean=2C standard deviation=2C and coefficient of variation. We also=
 calculate total analytical error based on a formula (TAE=E2=80=89=3D=E2=
=80=89bias=E2=80=89+=E2=80=892 SD) and compare the TAE with the allowable=
 total error recommended by CLSI and other sources. For example=2C if TAE=
 for platelets (based on reading control material 20 times) is less than 2=
5 percent (a CLSI recommended value)=2C we accept the target range; otherw=
ise=2C we reject it. However=2C since low concentrations of analytes are p=
rone to a higher degree of variation=2C the aforementioned target range ve=
rification process frequently fails. Is it necessary to accept or reject e=
stablished target values based on total analytical error? Or is there an a=
lternative way to do that?

A. It is not necessary to calculate total analytical error when establishi=
ng or verifying control ranges when implementing a new lot of control mate=
rial. Repetitive analysis of the new lot to determine mean=2C standard dev=
iation=2C and coefficient of variation is sufficient when establishing a n=
ew range for an unassayed control material or verifying a manufacturer=E2=
=80=99s range for an assayed control material. Acceptability limits for ve=
rifying a new lot of control are established by the laboratory director ba=
sed on the requirements for patient care and assay performance in that spe=
cific laboratory and are included in the lab=E2=80=99s written procedure.=
 Best practice is to use both an absolute value and a relative percentage=
 when setting acceptability limits. The absolute limit will apply at low a=
nalyte concentrations=2C and the percentage limit will apply at high analy=
te concentrations. Read more (https://www.captodayonline.com/qa-column-112=
2/) .

=C2=A9 2022 CAP TODAY=2C all rights reserved. The appearance of advertisin=
g in this message is not a CAP guarantee or endorsement of the product or=
 the claims made for the product by the manufacturer.

This email was sent to gloria@caldonbiotech.com (mailto:gloria@caldonbiotech.com)
why did I get this? (https://captodayonline.us2.list-manage.com/about?u=3D=
93f21bea2e282733bd0cd8d59&id=3D1abd017e9e&e=3D3507c8b6d9&c=3D993ff64907)   =
  unsubscribe from this list (https://captodayonline.us2.list-manage.com/u=
nsubscribe?u=3D93f21bea2e282733bd0cd8d59&id=3D1abd017e9e&e=3D3507c8b6d9&c=3D=
993ff64907)     update subscription preferences (https://captodayonline.us=
2.list-manage.com/profile?u=3D93f21bea2e282733bd0cd8d59&id=3D1abd017e9e&e=
=3D3507c8b6d9&c=3D993ff64907)
CAP TODAY . 325 Waukegan Road . Northfield=2C IL 60093 . USA
--_----------=_MCPart_2031158919
Content-Type: text/html; charset="utf-8"
Content-Transfer-Encoding: quoted-printable

<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www=
=2Ew3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<!doctype html>
<html>
    <head>
    <meta charset=3D"UTF-8">
    <!-- utf-8 works for most cases -->
    <meta name=3D"viewport" content=3D"width=3Ddevice-width=2C initial-sca=
le=3D1.0">
    <!-- Forcing initial-scale shouldn't be necessary -->
    <meta http-equiv=3D"X-UA-Compatible" content=3D"IE=3Dedge">
    <!-- Use the latest (edge) version of IE rendering engine -->

    <!-- The title tag shows in email notifications=2C like Android 4.4. -=
->
    <!-- Please use an inliner tool to convert all CSS to inline as inpage=
 or external CSS is removed by email clients -->
    <!-- important in CSS is used to prevent the styles of currently inlin=
e CSS from overriding the ones mentioned in media queries when correspondi=
ng screen sizes are encountered -->

    <!-- CSS Reset -->
    <style type=3D"text/css">
/* What it does: Remove spaces around the email design added by some email=
 clients. */
      /* Beware: It can remove the padding / margin and add a background c=
olor to the compose a reply window. */
html=2C  body {
=09margin: 0 !important;
=09padding: 0 !important;
=09height: 100% !important;
=09width: 100% !important;
}
/* What it does: Stops email clients resizing small text. */
* {
=09-ms-text-size-adjust: 100%;
=09-webkit-text-size-adjust: 100%;
}
/* What it does: Forces Outlook.com to display emails full width. */
=2EExternalClass {
=09width: 100%;
}
/* What is does: Centers email on Android 4.4 */
div[style*=3D"margin: 16px 0"] {
=09margin: 0 !important;
}
/* What it does: Stops Outlook from adding extra spacing to tables. */
table=2C  td {
=09mso-table-lspace: 0pt !important;
=09mso-table-rspace: 0pt !important;
}
/* What it does: Fixes webkit padding issue. Fix for Yahoo mail table alig=
nment bug. Applies table-layout to the first 2 tables then removes for any=
thing nested deeper. */
table {
=09border-spacing: 0 !important;
=09border-collapse: collapse !important;
=09table-layout: fixed !important;
=09margin: 0 auto !important;
}
table table table {
=09table-layout: auto;
}
/* What it does: Uses a better rendering method when resizing images in IE=
=2E */
img {
=09-ms-interpolation-mode: bicubic;
}
/* What it does: Overrides styles added when Yahoo's auto-senses a link. *=
/
=2Eyshortcuts a {
=09border-bottom: none !important;
}
/* What it does: Another work-around for iOS meddling in triggered links.=
 */
a[x-apple-data-detectors] {
=09color: inherit !important;
}
</style>

    <!-- Progressive Enhancements -->
    <style type=3D"text/css">
=09=09
=09=09h1 {
=09=09=09font-size:20px;
=09=09=09font-weight:normal;
=09=09=09line-height:25px;
=09=09}
=09=09
=09=09h2 {
=09=09=09font-size:16px;
=09=09=09font-weight:normal;
=09=09=09line-height:22px;
=09=09=09padding-bottom:5px;
=09=09=09margin:0;
=09=09=09
=09=09}
=09=09
=09=09a {
=09=09=09text-decoration:none;
=09=09=09color:#15377e;
=09=09=09padding:0;
=09=09=09margin:0;
=09=09=09
=09=09}

        /* What it does: Hover styles for buttons */
        .button-td=2C
        .button-a {
            transition: all 100ms ease-in;
        }
        .button-td:hover=2C
        .button-a:hover {
            background: #555555 !important;
            border-color: #555555 !important;
        }

        /* Media Queries */
        @media screen and (max-width: 600px) {

            .email-container {
                width: 100% !important;
            }

            /* What it does: Forces elements to resize to the full width o=
f their container. Useful for resizing images beyond their max-width. */
            .fluid=2C
            .fluid-centered {
                max-width: 100% !important;
                height: auto !important;
                margin-left: auto !important;
                margin-right: auto !important;
            }
            /* And center justify these ones. */
            .fluid-centered {
                margin-left: auto !important;
                margin-right: auto !important;
            }

            /* What it does: Forces table cells into full-width rows. */
            .stack-column=2C
            .stack-column-center {
                display: block !important;
                width: 100% !important;
                max-width: 100% !important;
                direction: ltr !important;
            }
            /* And center justify these ones. */
            .stack-column-center {
                text-align: center !important;
=09
            }

            /* What it does: Generic utility class for centering. Useful f=
or images=2C buttons=2C and nested tables. */
            .center-on-narrow {
                text-align: left !important;
                display: block !important;
                margin-left: auto !important;
                margin-right: auto !important;
                float: none !important;
=09=09=09=09}
            table.center-on-narrow {
                display: inline-block !important;
            }

        }

    </style>
    </head>
    <body bgcolor=3D"#ffffff" width=3D"100%" style=3D"margin: 0;" yahoo=3D=
"yahoo">
    <table bgcolor=3D"#ffffff" cellpadding=3D"0" cellspacing=3D"0" border=
=3D"0" height=3D"100%" width=3D"100%" style=3D"border-collapse:collapse;">
      <tr>
        <td><center style=3D"width: 100%;">

            <!-- Visually Hidden Preheader Text : BEGIN -->
            <div style=3D"display:none;font-size:1px;line-height:1px;max-h=
eight:0px;max-width:0px;opacity:0;overflow:hidden;mso-hide:all;font-family=
: sans-serif;">In cases of unexpected negative results in toxicology testi=
ng=2C avoid overinterpretation=2C know your assays and providers=2C and do=
n=E2=80=99t put off definitive testing when it=E2=80=99s needed=2C </div>
            <!-- Visually Hidden Preheader Text : END -->

            <!-- Email Header : BEGIN -->
            <table align=3D"center" width=3D"600" class=3D"email-container=
">
            <tr>
                <td style=3D"padding: 20px 0px 10px 0px; text-align: cente=
r"><a href=3D"https://captodayonline.us2.list-manage.com/track/click?u=3D9=
3f21bea2e282733bd0cd8d59&id=3D8d76686e69&e=3D3507c8b6d9"><img src=3D"http=
s://www.captodayonline.com/2022/eNEWS/Template/CAPTODAYLogo.jpg" width=3D"=
400" height=3D"102" alt=3D"alt_text" border=3D"0"></a></td>
              </tr>
=09=09=09=09
=09=09=09=09
=09=09=09
=09=09=09=09
          </table>
            <!-- Email Header : END -->

            <!-- Email Body : BEGIN -->
            <table cellspacing=3D"0" cellpadding=3D"0" border=3D"0" align=
=3D"center" bgcolor=3D"#ffffff" width=3D"600" class=3D"email-container">


            <!-- 1 Column Text : BEGIN -->
            <tr>
                <td style=3D"padding: 20px 20px 10px 20px; text-align: lef=
t; font-family: sans-serif; font-size: 12px; mso-height-rule: exactly; lin=
e-height: 18px; color: #555555;"><a href=3D"https://captodayonline.us2.lis=
t-manage.com/track/click?u=3D93f21bea2e282733bd0cd8d59&id=3Df716272e50&e=
=3D3507c8b6d9"><h1>In toxicology=2C puzzling out the unexpected negative<=
/h1></a>
=09=09=09=09=09
=09=09=09=09=09In cases of unexpected negative results in toxicology testi=
ng=2C avoid overinterpretation=2C know your assays and providers=2C and do=
n=E2=80=99t put off definitive testing when it=E2=80=99s needed=2C though=
 it=E2=80=99s not a panacea. That=E2=80=99s some of the advice Nicholas He=
ger=2C PhD=2C NRCC=2C medical director of clinical operations and lab supp=
ort and co-director of clinical chemistry at Tufts Medical Center=2C share=
d in an AACC session in July on toxicology investigations=2C focused on ur=
ine drug screening for compliance and pain management and using his lab=E2=
=80=99s patient cases.
=09=09=09=09
             </td>
              </tr>
=09=09=09=09<tr><td style=3D"padding:0px 20px 0px 20px"><hr style=3D"borde=
r: 1px solid #f4f4f4;"></td></tr>
=09=09=09=09
            <!-- Thumbnail Left=2C Text Right : BEGIN -->
            <tr>
                <td dir=3D"ltr" align=3D"center" valign=3D"top" width=3D"1=
00%" style=3D"padding: 25px 10px 10px 10px;"><table align=3D"center" borde=
r=3D"0" cellpadding=3D"0" cellspacing=3D"0" width=3D"100%">
                    <tr>
                    <td width=3D"56.00%" valign=3D"top" class=3D"stack-col=
umn-center"><table align=3D"center" border=3D"0" cellpadding=3D"0" cellspa=
cing=3D"0" width=3D"100%">
                        <tr>
                        <td dir=3D"ltr" valign=3D"top" style=3D"padding: 0=
 10px;"><a href=3D"https://captodayonline.us2.list-manage.com/track/click?=
u=3D93f21bea2e282733bd0cd8d59&id=3D74ae69e3db&e=3D3507c8b6d9" target=3D"_=
blank"><img src=3D"https://www.captodayonline.com/2022/eNEWS/120122_RocheV=
irology/300x250-LAB-v4-1.jpg" width=3D"300" height=3D"250" alt=3D"alt_text=
" border=3D"0" class=3D"fluid"></a></td>
                      </tr>
                      </table></td>
                    <td width=3D"44.00%" valign=3D"top" class=3D"stack-col=
umn-center"><table align=3D"center" border=3D"0" cellpadding=3D"0" cellspa=
cing=3D"0" width=3D"100%">
                        <tr>
                        <td dir=3D"ltr" valign=3D"top" style=3D"font-famil=
y: sans-serif; font-size: 12px; mso-height-rule: exactly; line-height: 18p=
x; color: #555555; padding: 10px; text-align: left;" class=3D"center-on-na=
rrow"><a href=3D"https://captodayonline.us2.list-manage.com/track/click?u=
=3D93f21bea2e282733bd0cd8d59&id=3Da95c2f3087&e=3D3507c8b6d9"><h2>FDA appr=
oves CDx for HER2-low metastatic breast cancer</h2></a>
                   The Food and Drug Administration approved Roche=E2=80=
=99s Pathway anti-HER2/neu (4B5) rabbit monoclonal primary antibody to ide=
ntify metastatic breast cancer patients with low HER2 expression for whom=
 Enhertu may be considered a targeted treatment. Enhertu is a specifically=
 engineered HER2-directed antibody drug conjugate jointly developed and co=
mmercialized by AstraZeneca and Daiichi Sankyo.
                            <br>
                         </td>
                      </tr>
                      </table></td>
                  </tr>
                  </table></td>
              </tr>
            <!-- Thumbnail Left=2C Text Right : END -->
           <tr><td style=3D"padding:0px 20px 0px 20px"><hr style=3D"border=
: 1px solid #f4f4f4;"></td></tr>
            <!-- Thumbnail Right=2C Text Left : BEGIN -->
=09=09=09
            <tr>
                <td dir=3D"rtl" align=3D"center" valign=3D"top" width=3D"1=
00%" style=3D"padding: 10px;"><table align=3D"center" border=3D"0" cellpad=
ding=3D"0" cellspacing=3D"0" width=3D"100%">
                    <tr>
                    <td width=3D"33.33%" class=3D"stack-column-center"><ta=
ble align=3D"center" border=3D"0" cellpadding=3D"0" cellspacing=3D"0" widt=
h=3D"100%">
                        <tr>
                        <td dir=3D"ltr" valign=3D"top" style=3D"padding: 0=
 10px;"><a href=3D"https://captodayonline.us2.list-manage.com/track/click?=
u=3D93f21bea2e282733bd0cd8d59&id=3D478acefb42&e=3D3507c8b6d9" target=3D"_=
blank"><img src=3D"https://www.captodayonline.com/2022/eNEWS/120122_RocheV=
irology/160x600-LAB-v3-1.jpg" width=3D"160" height=3D"600px" alt=3D"alt_te=
xt" border=3D"0" class=3D"center-on-narrow"></a></td>
                      </tr>
                      </table></td>
                    <td width=3D"66.66%" valign=3D"top" class=3D"stack-col=
umn-center"><table align=3D"center" border=3D"0" cellpadding=3D"0" cellspa=
cing=3D"0" width=3D"100%">
                        <tr>
                        <td dir=3D"ltr" valign=3D"top" style=3D"font-famil=
y: sans-serif; font-size: 12px; mso-height-rule: exactly; line-height: 18p=
x; color: #555555; padding: 10px; text-align: left;" class=3D"center-on-na=
rrow">
<h1><a href=3D"https://captodayonline.us2.list-manage.com/track/click?u=3D=
93f21bea2e282733bd0cd8d59&id=3Dbf75d0a457&e=3D3507c8b6d9">Q&amp;A column<=
/a></h1>
<strong>Q. I want to inquire about verification of target mean/ranges for=
 hematology analytes. We run a control material 20 times and calculate sta=
tistics such as mean=2C standard deviation=2C and coefficient of variation=
=2E We also calculate total analytical error based on a formula (TAE=E2=80=
=89=3D=E2=80=89bias=E2=80=89+=E2=80=892 SD) and compare the TAE with the a=
llowable total error recommended by CLSI and other sources.</strong> For e=
xample=2C if TAE for platelets (based on reading control material 20 times=
) is less than 25 percent (a CLSI recommended value)=2C we accept the targ=
et range; otherwise=2C we reject it. However=2C since low concentrations o=
f analytes are prone to a higher degree of variation=2C the aforementioned=
 target range verification process frequently fails. Is it necessary to ac=
cept or reject established target values based on total analytical error?=
 Or is there an alternative way to do that?
                            <br><br>
<strong>A.</strong> It is not necessary to calculate total analytical erro=
r when establishing or verifying control ranges when implementing a new lo=
t of control material. Repetitive analysis of the new lot to determine mea=
n=2C standard deviation=2C and coefficient of variation is sufficient when=
 establishing a new range for an unassayed control material or verifying a=
 manufacturer=E2=80=99s range for an assayed control material. Acceptabili=
ty limits for verifying a new lot of control are established by the labora=
tory director based on the requirements for patient care and assay perform=
ance in that specific laboratory and are included in the lab=E2=80=99s wri=
tten procedure. Best practice is to use both an absolute value and a relat=
ive percentage when setting acceptability limits. The absolute limit will=
 apply at low analyte concentrations=2C and the percentage limit will appl=
y at high analyte concentrations. <a href=3D"https://captodayonline.us2.li=
st-manage.com/track/click?u=3D93f21bea2e282733bd0cd8d59&id=3D11207a1808&e=
=3D3507c8b6d9"><strong>Read more</strong></a>.

                           </td>
                      </tr>
                      </table></td>
                  </tr>
                  </table></td>
              </tr>
            <!-- Thumbnail Right=2C Text Left : END -->

          </table>
            <!-- Email Body : END -->

            <!-- Email Footer : BEGIN -->
            <table align=3D"center" width=3D"600" class=3D"email-container=
">
            <tr>
                <td style=3D"padding: 40px 10px;width: 100%;font-size: 12p=
x; font-family: sans-serif; mso-height-rule: exactly; line-height:18px; te=
xt-align: center; color: #888888;">
                <br>
                <br>
                =C2=A9 2022 CAP TODAY=2C all rights reserved. The appearan=
ce of advertising in this message is not a CAP guarantee or endorsement of=
 the product or the claims made for the product by the manufacturer.<br>
                </td>
              </tr>
          </table>
            <!-- Email Footer : END -->

          </center></td>
      </tr>
    </table>
            <center>
                <br>
                <br>
                <br>
                <br>
                <br>
                <br>
                <table border=3D"0" cellpadding=3D"0" cellspacing=3D"0" wi=
dth=3D"100%" id=3D"canspamBarWrapper" style=3D"background-color:#FFFFFF; b=
order-top:1px solid #E5E5E5;">
                    <tr>
                        <td align=3D"center" valign=3D"top" style=3D"paddi=
ng-top:20px; padding-bottom:20px;">
                            <table border=3D"0" cellpadding=3D"0" cellspac=
ing=3D"0" id=3D"canspamBar">
                                <tr>
                                    <td align=3D"center" valign=3D"top" st=
yle=3D"color:#606060; font-family:Helvetica=2C Arial=2C sans-serif; font-s=
ize:11px; line-height:150%; padding-right:20px; padding-bottom:5px; paddin=
g-left:20px; text-align:center;">
                                        This email was sent to <a href=3D"=
mailto:gloria@caldonbiotech.com" target=3D"_blank" style=3D"color:#404040 !importa=
nt;">gloria@caldonbiotech.com</a>
                                        <br>
                                        <a href=3D"https://captodayonline.=
us2.list-manage.com/about?u=3D93f21bea2e282733bd0cd8d59&id=3D1abd017e9e&e=
=3D3507c8b6d9&c=3D993ff64907" target=3D"_blank" style=3D"color:#404040 !impo=
rtant;"><em>why did I get this?</em></a>&nbsp;&nbsp;&nbsp;&nbsp;<a href=3D=
"https://captodayonline.us2.list-manage.com/unsubscribe?u=3D93f21bea2e2827=
33bd0cd8d59&id=3D1abd017e9e&e=3D3507c8b6d9&c=3D993ff64907" style=3D"color:#4=
04040 !important;">unsubscribe from this list</a>&nbsp;&nbsp;&nbsp;&nbsp;<=
a href=3D"https://captodayonline.us2.list-manage.com/profile?u=3D93f21bea2=
e282733bd0cd8d59&id=3D1abd017e9e&e=3D3507c8b6d9&c=3D993ff64907" style=3D"col=
or:#404040 !important;">update subscription preferences</a>
                                        <br>
                                        CAP TODAY &middot; 325 Waukegan Ro=
ad &middot; Northfield=2C IL 60093 &middot; USA
                                        <br>
                                        <br>

                                    </td>
                                </tr>
                            </table>
                        </td>
                    </tr>
                </table>
                <style type=3D"text/css">
                    @media only screen and (max-width: 480px){
                        table#canspamBar td{font-size:14px !important;}
                        table#canspamBar td a{display:block !important; ma=
rgin-top:10px !important;}
                    }
                </style>
            </center><img src=3D"https://captodayonline.us2.list-manage.co=
m/track/open.php?u=3D93f21bea2e282733bd0cd8d59&id=3D993ff64907&e=3D3507c8b6d9" height=3D"1" width=3D"1" alt=3D""></body>
</html>
--_----------=_MCPart_2031158919--
